Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Surgical Oncology ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): A multicentre, open-label, randomised, phase 3 trial.Lancet Oncol. 2020; 21: 1366-1377
- NBTXR3, a first-in-class radioenhancer hafnium oxide nanoparticle, plus radiotherapy versus radiotherapy alone in patients with locally advanced soft-tissue sarcoma (act.in.sarc): A multicentre, phase 2-3, randomised, controlled trial.Lancet Oncol. 2019; 20: 1148-1159
- Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: Final results of a randomized trial from italian (ISG), spanish (GEIS), french (FSG), and polish (PSG) sarcoma groups.J Clin Oncol. 2020; 38: 2178-2186
- Impact of perioperative chemotherapy and radiotherapy in patients with primary extremity soft tissue sarcoma: Retrospective analysis across major histological subtypes and major reference centres.Eur J Cancer. 2018; 105: 19-27
- Dose reduction of preoperative radiotherapy in myxoid liposarcoma: A nonrandomized controlled trial.JAMA Oncol. 2021; 7: e205865
- Adjuvant chemotherapy for localised resectable soft tissue sarcoma in adults.Cochrane Database Syst Rev. 2000; 4: CD001419
- A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma.Cancer. 2008; 113: 573-581
- The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: Revisiting the results of the EORTC-STBSG 62931 randomised trial.Eur J Cancer. 2019; 109: 51-60
- Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: A sarculator-based risk stratification analysis of the ISG-STS 1001 randomized trial.Cancer. 2022; 128: 85-93
- Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): An international, open-label, randomised, controlled, phase 3, multicentre trial.Lancet Oncol. 2017; 18: 812-822
- DIGITAL FOREST srl. Applestore.(Available at:) (Accessed February 18, 2022)
- First-in-human study testing a new radioenhancer using nanoparticles (NBTXR3) activated by radiation therapy in patients with locally advanced soft tissue sarcomas.Clin Cancer Res. 2017; 23: 908-917
- Evaluation of response after neoadjuvant treatment in soft tissue sarcomas; the european organization for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC-STBSG) recommendations for pathological examination and reporting.Eur J Cancer. 2016; 53: 84-95
- Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: A randomised trial.Lancet. 2002; 359: 2235-2241
- The treatment of soft-tissue sarcomas of the extremities: Prospective randomized evaluations of (1) limb-sparing surgery plus radiation therapy compared with amputation and (2) the role of adjuvant chemotherapy.Ann Surg. 1982; 196: 305-315
- Long-term results of a prospective randomized trial of adjuvant brachytherapy in soft tissue sarcoma.J Clin Oncol. 1996; 14: 859-868
- Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity.J Clin Oncol. 1998; 16: 197-203
- Efficacy of adjuvant radiation therapy in the treatment of soft tissue sarcoma of the extremity: 20-year follow-up of a randomized prospective trial.Ann Surg Oncol. 2014; 21: 2484-2489
- Late radiation morbidity following randomization to preoperative versus postoperative radiotherapy in extremity soft tissue sarcoma.Radiother Oncol. 2005; 75: 48-53
- Phase II study of neoadjuvant chemotherapy and radiation therapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation therapy oncology group trial 9514.J Clin Oncol. 2006; 24: 619-625
- Long-term results of a phase 2 study of neoadjuvant chemotherapy and radiotherapy in the management of high-risk, high-grade, soft tissue sarcomas of the extremities and body wall: Radiation therapy oncology group trial 9514.Cancer. 2010; 116: 4613-4621
- Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): A multicentre randomised controlled trial.Lancet Oncol. 2012; 13: 1045-1054
- Short, full-dose adjuvant chemotherapy (CT) in high-risk adult soft tissue sarcomas (STS): Long-term follow-up of a randomized clinical trial from the italian sarcoma group and the spanish sarcoma group.Ann Oncol. 2016; 27: 2283-2288
- Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.J Clin Oncol. 2008; 26: 620-625
- Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: A randomised controlled trial.Lancet. 2006; 368: 1329-1338
- Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): An international, multicentre, randomised, placebo-controlled, phase 3 trial.Lancet. 2013; 381: 295-302
- Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): A double-blind, randomised, placebo-controlled, phase 3 trial.Lancet Oncol. 2020; 21: 923-934
- Avapritinib versus regorafenib in locally advanced unresectable or metastatic GI stromal tumor: A randomized, open-label phase III study.J Clin Oncol. 2021; 39: 3128-3139
- Two hundred gastrointestinal stromal tumors: Recurrence patterns and prognostic factors for survival.Ann Surg. 2000; 231: 51-58
- One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: A randomized trial.JAMA. 2012; 307: 1265-1272
- Survival outcomes associated with 3 years vs 1 year of adjuvant imatinib for patients with high-risk gastrointestinal stromal tumors: An analysis of a randomized clinical trial after 10-year follow-up.JAMA Oncol. 2020; 6: 1241-1246
- Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: A randomised, double-blind, placebo-controlled trial.Lancet. 2009; 373: 1097-1104
- Efficacy and tolerability of 5-year adjuvant imatinib treatment for patients with resected intermediate- or high-risk primary gastrointestinal stromal tumor: The PERSIST-5 clinical trial.JAMA Oncol. 2018; 4: e184060
- Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): Early results of RTOG 0132/ACRIN 6665.J Surg Oncol. 2009; 99: 42-47
- Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: Long-term follow-up results of radiation therapy oncology group 0132.Ann Surg Oncol. 2012; 19: 1074-1080
- Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: Proposal of new computed tomography response criteria.J Clin Oncol. 2007; 25: 1753-1759
- Long-term results of adjuvant imatinib mesylate in localized, high-risk, primary gastrointestinal stromal tumor: ACOSOG Z9000 (alliance) intergroup phase 2 trial.Ann Surg. 2013; 258: 422-429
- Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: The ACOSOG Z9001 trial.J Clin Oncol. 2014; 32: 1563-1570
- Adjuvant imatinib for high-risk GI stromal tumor: Analysis of a randomized trial.J Clin Oncol. 2016; 34: 244-250
- Time to definitive failure to the first tyrosine kinase inhibitor in localized GI stromal tumors treated with imatinib as an adjuvant: A european organisation for research and treatment of cancer soft tissue and bone sarcoma group intergroup randomized trial in collaboration with the australasian gastro-intestinal trials group, UNICANCER, french sarcoma group, italian sarcoma group, and spanish group for research on sarcomas.J Clin Oncol. 2015; 33: 4276-4283
- A randomized, phase II study of preoperative plus postoperative imatinib in GIST: Evidence of rapid radiographic response and temporal induction of tumor cell apoptosis.Ann Surg Oncol. 2009; 16: 910-919
- Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: A prospective randomised trial in china.Eur J Cancer. 2014; 50: 1772-1778
- Intraoperative radiotherapy in retroperitoneal sarcomas. final results of a prospective, randomized, clinical trial.Arch Surg. 1993; 128: 402-410
- Preoperative radiation therapy and iododeoxyuridine for large retroperitoneal sarcomas.Int J Radiat Oncol Biol Phys. 1995; 31: 87-92
- Initial results of a trial of preoperative external-beam radiation therapy and postoperative brachytherapy for retroperitoneal sarcoma.Ann Surg Oncol. 2002; 9: 346-354
- Combined management of retroperitoneal sarcoma with dose intensification radiotherapy and resection: Long-term results of a prospective trial.Radiother Oncol. 2014; 110: 165-171
- Phase I trial of preoperative concurrent doxorubicin and radiation therapy, surgical resection, and intraoperative electron-beam radiation therapy for patients with localized retroperitoneal sarcoma.J Clin Oncol. 2003; 21: 3092-3097
- Clinical phase I/II trial to investigate preoperative dose-escalated intensity-modulated radiation therapy (IMRT) and intraoperative radiation therapy (IORT) in patients with retroperitoneal soft tissue sarcoma: Interim analysis.BMC Cancer. 2014; 14 (617-2407-14-617)
- Preoperative chemo-radiation therapy for localised retroperitoneal sarcoma: A phase I-II study from the italian sarcoma group.Eur J Cancer. 2014; 50: 784-792
Article info
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
